Core Viewpoint - The collaboration between Beijing JACOS and AstraZeneca involves the development and commercialization of the KRAS inhibitor JAB-23E73, with AstraZeneca receiving exclusive global rights outside of China [1] Group 1: Agreement Details - Beijing JACOS has entered into a licensing and collaboration agreement with AstraZeneca for the development of JAB-23E73 [1] - AstraZeneca will be responsible for all costs and activities related to the further development and commercialization of JAB-23E73 in its designated regions [1] - The agreement includes a joint development and commercialization framework for the product in China, excluding Hong Kong, Macau, and Taiwan [1] Group 2: Financial Terms - Beijing JACOS is entitled to receive an upfront payment of $100 million from AstraZeneca [1] - Additional milestone payments could total up to $1.915 billion based on the achievement of various development, regulatory, and commercial milestones [1] - Upon successful commercialization, Beijing JACOS will receive tiered royalties based on the net sales of the licensed product [1]
加科思-B(01167)附属与阿斯利康订立许可与合作协议